“I Feel Happy Again”: Methylphenidate Supports Health-Related Quality of Life in Survivors of Pediatric Brain Tumor

Verity, Sarah J; Bell, Lauren; Ryles, Jade; Hill, Rebecca

doi:10.3390/children9071058

Cited by 4 publications

(7 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current case series describes the assessment of intelligence provided at six years old or as soon after six years as the child was diagnosed (D1), baseline immediately prior to use of methylphenidate (B1), at one year on methylphenidate (T1), and three years on methylphenidate (T2). Measures of attention and HRQoL collected from this cohort are described in detail in previous studies [7,8,14], using the Test of Everyday Attention for Children (TEACh-2) [28], the SNAP IV [29], and the PEDS-QL [30]. Side effects were measured using Barkley's Stimulant Side Effect Rating Scale [31] and via clinical interview.…”

Section: Methodsmentioning

confidence: 99%

“…Participant data in the current retrospective clinical case series were derived from a previous service evaluation study assessing the utility of methylphenidate in managing the attentional deficit in survivors of a paediatric brain tumour [14]. Participant selection for suitability of methylphenidate treatment in this study and associated demographic details have been described previously [7,8,14]. In brief, eligible patients for the service evaluation were aged between 5.0 and 15.5 years at recruitment; had a General Ability Index ≥ 50; had a brain tumour; had completed initial cancer treatment at least 12 months prior to baseline assessment; and had hydrocephalus at diagnosis and/or received cranial radiotherapy.…”

Section: Clinical Samplementioning

confidence: 99%

“…Their randomised controlled trial shows methylphenidate to effectively mediate treatment-related processing speed and attentional deficits whilst producing minimal unwanted side effects. Alongside measurable cognitive benefits, methylphenidate has been shown to be highly favourable to patients and parents and to produce a marked increase in the quality of survivorship [7,8].…”

Section: Introductionmentioning

confidence: 99%

“…The current case series describes the trajectory of intellectual development in six survivors of a paediatric brain tumour over a minimum of three years of use of methylphenidate. These patient data, alongside a discussion of learning points from our previously published studies, were used as a conduit for identifying salient questions relating to the use of methylphenidate in a paediatric brain tumour [7,8,14]. These questions will inform our analyses of a study in progress with a larger cohort.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Key Questions on the Long-Term Utility of Methylphenidate in Paediatric Brain Tumour Survivorship: A Retrospective Clinical Case Series

Hagan,

Verity

2024

Children

Self Cite

View full text Add to dashboard Cite

Methylphenidate has an established role in the management of attention-deficit hyperactivity disorder and attentional deficit secondary to brain injury. Increasingly, methylphenidate is considered for the attentional deficit in paediatric brain tumour survivors. A small number of studies have explored the benefit of methylphenidate in this population; however, studies are of short duration and do not address the impact of medium to long-term use of methylphenidate on intellectual function. We identified six patients who are survivors of a paediatric brain tumour aged 12–18 years with greater than three years of use of methylphenidate for inclusion in a clinical case series. We used this patient cohort to identify key questions to inform a future long-term cohort study. Linear mixed model and reliable change index analyses were performed on the data. Reliable change index analyses showed benefits to working memory (n = 3), processing speed (n = 2), and full-scale IQ (n = 4) performance for some patients. This exploratory case series suggests the potential medium to long-term benefit of methylphenidate in brain tumour survivorship, indicating the need for larger, appropriately powered studies. These patient data, alongside a discussion of learning points from our previously published studies, are used as a conduit for the identification of questions relating to the use of methylphenidate in a paediatric brain tumour.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Clinical Samplementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Key Questions on the Long-Term Utility of Methylphenidate in Paediatric Brain Tumour Survivorship: A Retrospective Clinical Case Series

Hagan,

Verity

2024

Children

Self Cite

View full text Add to dashboard Cite

show abstract

“…We worked with an MSc postgraduate student, Lauren Bell, to help us share our patients' experiences. You can read this in a paper titled "I feel happy again": Methylphenidate Supports Health-Related Quality of Life in Survivors of Paediatric Brain Tumour [7]. Lauren looked at questionnaire data that we had collected from 12 of our patients.…”

mentioning

confidence: 99%

Is Methylphenidate Useful to Survivors of Childhood Brain Tumour? An Accessible Summary of Recent Research

2024

Psychol J Res Open

View full text Add to dashboard Cite

Many children and young people experience long-term difficulties after having a brain tumour. This paper discusses interventions using the medication methylphenidate and describes the current research in this area being conducted at the Great North Children's Hospital (Newcastle upon Tyne) and Newcastle University Centre for Cancer. The children, young people, and their families who use our hospital tell us that some of their most challenging difficulties only happened once the brain tumour treatment had finished. Some survivors of childhood brain tumour are left with lifelong disabilities that result from their cancer or treatment. These disabilities are often related to brain injury, and can be relatively invisible to the general public. Some disabilities only become apparent over the time following treatment. These are known as 'long-term late effects' . The most common long-term late effect that is reported after childhood brain tumour is an acquired brain injury. We see signs of an acquired brain injury following brain tumour in behaviour such as reduced attention, a reduction in ability to remember things, a slowing down of how quickly the child can take in information, and an impact on their academic performance and overall intellectual ability (IQ). Depending on the location of the tumour, brain injury can present in a different way. It is important to remember that the term 'brain injury' refers to any injury affecting the brain, so information on brain injury on the internet may not apply to the specific injury a child has acquired. A child can develop brain injury after a brain tumour due to one or many different factors, including any build-up of fluid in the brain before the tumour was discovered (hydrocephalus), surgery, post-surgical complications (such as posterior fossa syndrome), certain chemotherapies, or radiotherapy. Generally, the younger a child is at the time of diagnosis, the more likely they are to experience significant late effects.We have worked with a number of patients and their families in Newcastle at the Great North Children's Hospital to help us understand what the role of methylphenidate might be in helping to reduce long-term late effects that affect intellectual and academic ability. Methylphenidate is a medication that is used for a few different reasons. Usually people have heard of methylphenidate by one of its brand names, 'Ritalin' , which they know is used for children with Attention Deficit Hyperactivity Disorder (ADHD). We do not use this

show abstract

Methylphenidate improves cognitive function and health-related quality of life in survivors of childhood brain tumours

Verity

Halliday

Hill

et al. 2022

Neuropsychological Rehabilitation

View full text Add to dashboard Cite

“I Feel Happy Again”: Methylphenidate Supports Health-Related Quality of Life in Survivors of Pediatric Brain Tumor

Cited by 4 publications

References 33 publications

Key Questions on the Long-Term Utility of Methylphenidate in Paediatric Brain Tumour Survivorship: A Retrospective Clinical Case Series

Key Questions on the Long-Term Utility of Methylphenidate in Paediatric Brain Tumour Survivorship: A Retrospective Clinical Case Series

Is Methylphenidate Useful to Survivors of Childhood Brain Tumour? An Accessible Summary of Recent Research

Methylphenidate improves cognitive function and health-related quality of life in survivors of childhood brain tumours

Contact Info

Product

Resources

About